On June 24, Hengrui Medicine (01276.HK) rose 3.47% in regular trading, trading at HK$57.9/share, with turnover of HK$26.10 million. The stock continued its upward momentum following a 3.73% gain in the previous session.

On the news front, the European Medicines Agency officially accepted the company's marketing authorization application for revulutamide tablets, marking the first self-developed innovative drug submitted by Hengrui Medicine for EU market approval. The drug is indicated for use in combination with androgen deprivation therapy for the treatment of adult male patients with high tumor burden metastatic hormone-sensitive prostate cancer, representing a substantial milestone in the company's internationalization strategy.

Meanwhile, the innovative drug sector broadly strengthened, with multiple Hong Kong-listed pharmaceutical stocks rising in tandem, creating a visible sector linkage effect. Within the Pharmaceuticals sector, ASYMCHEM gained 7.23%, Shandong Xinhua rose 3.67%, SBP Group advanced 2.52%, CSPC Pharma added 1.35%, and Hansoh Pharma climbed 1.08%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)